Forbes contributors publish independent expert analyses and insights. Mark Faithfull is London-based and covers retail and real estate German sportswear giant Puma is set to cut 900 corporate jobs ...
The story of Puma Biotechnology has been one of the most dramatic in the drug business. Three years ago Puma's chief executive, Alan Auerbach, was a billionaire based on his holdings in the company.
Puma Biotechnology ($PBYI) investors have been giddy about their prized biotech kitty. The cancer drug developer's shares have risen more than 50% in 2013 as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results